P499 Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?
Abstract Background Higher infliximab trough levels (ITL) have been shown to be associated with better rates of clinical remission and mucosal healing. Transmural healing (TMH) assessed by cross-sectional imaging [such as intestinal ultrasound (IUS)] is emerging as a potential target in Crohn′s dise...
Saved in:
Published in | Journal of Crohn's and colitis Vol. 16; no. Supplement_1; p. i462 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
21.01.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Higher infliximab trough levels (ITL) have been shown to be associated with better rates of clinical remission and mucosal healing. Transmural healing (TMH) assessed by cross-sectional imaging [such as intestinal ultrasound (IUS)] is emerging as a potential target in Crohn′s disease (CD) treatment, but whether there is any relation with ITL remains unclear. Our goal was to investigate the association between ITL and bowel wall thickness (BWT) in patients with CD after induction therapy with IFX.
Methods
Prospective multicentric cohort study of CD patients who started IFX in mono or combination therapy. Patients performed IUS and ITL at weeks 0 and 14. TMH was defined as BWT ≤3 mm in the most affected segment. A ROC curve was plotted to determine the best cut-off point of ITL to predict TMH. Chi-square test, Mann-Whitney test and Spearman correlation were performed to assess the ITL relation with BWT.
Results
We included 57 patients, 30 (53%) of whom were men with mean age of 36±15 years. Disease extension according to Montreal classification was L1 in 19 (33%), L2 in 8 (14%) and L3 in 30 (53%) patients; 6 (11%) patients also had L4 extension and 19 (33%) patients had perianal disease. Disease behavior was B1 in 36 (63%), B2 in 13 (23%) and B3 in 8 (14%) of patients. Most patients (61%) were under immunomodulators and 15 (26%) were under corticosteroids when infliximab was started; most (88%) were naïve for infliximab. At week 0, all patients had endoscopic activity and 97% had increased BWT at the most affected segment. The most affected segment on IUS at week 0 was the terminal ileum in 38 (67%) patients and the ascending, transverse, descending and sigmoid colon in 5 (9%), 2 (3%), 7 (12%) and 5 (9%) patients, respectively. There was a very good agreement between IUS and colonoscopy for evaluation of the most affected segment at baseline (kappa 0.81, p<0.001). Median ITL at week 14 was 4.30 μg/ml (IQR 0.01–21). TMH at week 14 was achieved in 13 (23%) patients. ITL and BWT at week 14 were negatively correlated, with a fair correlation (r=-0.3, p=0.03). The AUC of ITL for BWT was 0.661 (best cut-off value 7.65, sensitivity 54%, specificity 89%). ITL ≥7.65 μg/ml was associated with higher rates of TMH (44% vs 15%, OR 4.47 [95%CI 1.2–16.4], p=0.04).
Conclusion
In our cohort of CD patients completing induction therapy with infliximab, higher ITL were associated with higher ultrasonographic transmural healing rates. The best cut-off for predicting TMH was ITL above 7.65μg/ml. |
---|---|
AbstractList | Abstract
Background
Higher infliximab trough levels (ITL) have been shown to be associated with better rates of clinical remission and mucosal healing. Transmural healing (TMH) assessed by cross-sectional imaging [such as intestinal ultrasound (IUS)] is emerging as a potential target in Crohn′s disease (CD) treatment, but whether there is any relation with ITL remains unclear. Our goal was to investigate the association between ITL and bowel wall thickness (BWT) in patients with CD after induction therapy with IFX.
Methods
Prospective multicentric cohort study of CD patients who started IFX in mono or combination therapy. Patients performed IUS and ITL at weeks 0 and 14. TMH was defined as BWT ≤3 mm in the most affected segment. A ROC curve was plotted to determine the best cut-off point of ITL to predict TMH. Chi-square test, Mann-Whitney test and Spearman correlation were performed to assess the ITL relation with BWT.
Results
We included 57 patients, 30 (53%) of whom were men with mean age of 36±15 years. Disease extension according to Montreal classification was L1 in 19 (33%), L2 in 8 (14%) and L3 in 30 (53%) patients; 6 (11%) patients also had L4 extension and 19 (33%) patients had perianal disease. Disease behavior was B1 in 36 (63%), B2 in 13 (23%) and B3 in 8 (14%) of patients. Most patients (61%) were under immunomodulators and 15 (26%) were under corticosteroids when infliximab was started; most (88%) were naïve for infliximab. At week 0, all patients had endoscopic activity and 97% had increased BWT at the most affected segment. The most affected segment on IUS at week 0 was the terminal ileum in 38 (67%) patients and the ascending, transverse, descending and sigmoid colon in 5 (9%), 2 (3%), 7 (12%) and 5 (9%) patients, respectively. There was a very good agreement between IUS and colonoscopy for evaluation of the most affected segment at baseline (kappa 0.81, p<0.001). Median ITL at week 14 was 4.30 μg/ml (IQR 0.01–21). TMH at week 14 was achieved in 13 (23%) patients. ITL and BWT at week 14 were negatively correlated, with a fair correlation (r=-0.3, p=0.03). The AUC of ITL for BWT was 0.661 (best cut-off value 7.65, sensitivity 54%, specificity 89%). ITL ≥7.65 μg/ml was associated with higher rates of TMH (44% vs 15%, OR 4.47 [95%CI 1.2–16.4], p=0.04).
Conclusion
In our cohort of CD patients completing induction therapy with infliximab, higher ITL were associated with higher ultrasonographic transmural healing rates. The best cut-off for predicting TMH was ITL above 7.65μg/ml. |
Author | Cúrdia Gonçalves, T Torres, J Castro, F Cotter, J Sousa, R Pereira, F Macedo, G Revés, J Moreira, M J Macedo, C Ferreira, M Freitas, M Frias Gomes, C Palmela, C Morão, B Caldeira, A Coelho, R Glória, L |
Author_xml | – sequence: 1 givenname: B surname: Morão fullname: Morão, B organization: Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal – sequence: 2 givenname: C surname: Frias Gomes fullname: Frias Gomes, C organization: Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal – sequence: 3 givenname: J surname: Revés fullname: Revés, J organization: Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal – sequence: 4 givenname: T surname: Cúrdia Gonçalves fullname: Cúrdia Gonçalves, T organization: Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastroenterology, Guimarães/Braga, Portugal – sequence: 5 givenname: M surname: Freitas fullname: Freitas, M organization: Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastroenterology, Guimarães/Braga, Portugal – sequence: 6 givenname: F surname: Castro fullname: Castro, F organization: Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastroenterology, Guimarães/Braga, Portugal – sequence: 7 givenname: M J surname: Moreira fullname: Moreira, M J organization: Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastroenterology, Guimarães/Braga, Portugal – sequence: 8 givenname: J surname: Cotter fullname: Cotter, J organization: Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastroenterology, Guimarães/Braga, Portugal – sequence: 9 givenname: F surname: Pereira fullname: Pereira, F organization: Unidade Local de Saúde de Castelo Branco- EPE- Hospital Amato Lusitano, Gastroenterology, Castelo Branco, Portugal – sequence: 10 givenname: A surname: Caldeira fullname: Caldeira, A organization: Unidade Local de Saúde de Castelo Branco- EPE- Hospital Amato Lusitano, Gastroenterology, Castelo Branco, Portugal – sequence: 11 givenname: R surname: Sousa fullname: Sousa, R organization: Unidade Local de Saúde de Castelo Branco- EPE- Hospital Amato Lusitano, Gastroenterology, Castelo Branco, Portugal – sequence: 12 givenname: R surname: Coelho fullname: Coelho, R organization: Centro Hospitalar de São João, Gastroenterology, Porto, Portugal – sequence: 13 givenname: G surname: Macedo fullname: Macedo, G organization: Centro Hospitalar de São João, Gastroenterology, Porto, Portugal – sequence: 14 givenname: C surname: Macedo fullname: Macedo, C organization: Centro Hospitalar Universitário de Coimbra, Gastroenterology, Coimbra, Portugal – sequence: 15 givenname: M surname: Ferreira fullname: Ferreira, M organization: Centro Hospitalar Universitário de Coimbra, Gastroenterology, Coimbra, Portugal – sequence: 16 givenname: L surname: Glória fullname: Glória, L organization: Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal – sequence: 17 givenname: J surname: Torres fullname: Torres, J organization: Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal – sequence: 18 givenname: C surname: Palmela fullname: Palmela, C organization: Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal |
BookMark | eNo1kEtOwzAURS1UJNrCDhh4A2nt2PmYCaoqflIlGMA4chw7dpXalZ1QOmMbLIMtsRLcUkbvPencq6czASPrrATgGqMZRozMpRAuWQsxX695nZJ0lqf5GRjjssgTSgs2Ou4kYYzmF2ASwhqhjGVFOQbfL5QxuBBChmBsC4eu9zw461rPt9oIGE8bNoPnHdSSdwfGWLjlvZG2D3Bneg2X3mn78_kVYGOC5EFCrnrpI9gMojfOwl7L2Lf_w41VnfkwG17fwKDd0DVwFyNmA5XzUJtWH7P_UHzBDa2GnXyXXbi9BOeKd0FeneYUvN3fvS4fk9Xzw9NysUoEpmme1IrzVDFFCBIESZY1RKKS5jXHVJaNIBwj2uSYqZKUJSKCUpziWpWIq5wVGZkC-tcrvAvBS1VtfXzH7yuMqoP26qC9itqrk_Yqaie_W2KBMA |
CitedBy_id | crossref_primary_10_1093_ibd_izac186 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1093/ecco-jcc/jjab232.626 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1876-4479 |
EndPage | i462 |
ExternalDocumentID | 10_1093_ecco_jcc_jjab232_626 |
GroupedDBID | --- --K 0R~ 1B1 1~. 1~5 4.4 48X 4G. 5GY 5WD 7-5 71M AABZA AACZT AAMVS AAOGV AAPQZ AAPXW AARHZ AASNB AAUAY AAVAP AAYXX ABBQC ABDBF ABEUO ABIXL ABJNI ABNHQ ABPTD ABQLI ABQNK ABWST ABXVV ACGFS ACUFI ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADJQC ADQBN ADRIX ADRTK ADVEK ADYVW AEGPL AEJOX AEKER AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGQXC AGSYK AGUTN AGYEJ AJEEA AJRQY ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT ATGXG AVWKF AXUDD BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM CDBKE CITATION CS3 DAKXR DILTD DU5 EBS ENERS EO8 EO9 EP2 EP3 F5P FDB FECEO FLUFQ FNPLU FOEOM FOTVD FQBLK GAUVT GBLVA GJXCC H13 HAR IHE J1W J21 KOP KSI KSN MHKGH MO0 N9A NOMLY NOYVH O-L OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OPAEJ OVD OWPYF OZT P-8 P-9 P2P PAFKI PC. PEELM Q5Y RIG ROX RPZ RUSNO RXO SDF SDG SEL SES TEORI TJX YAYTL YKOAZ YXANX |
ID | FETCH-LOGICAL-c1426-bfaa2f9f330c30e95d3e0846ba14e8dc3a104d619f838803c44121bf80af69753 |
ISSN | 1873-9946 |
IngestDate | Fri Aug 23 09:42:16 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1426-bfaa2f9f330c30e95d3e0846ba14e8dc3a104d619f838803c44121bf80af69753 |
OpenAccessLink | https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i462/42252759/jjab232.626.pdf |
ParticipantIDs | crossref_primary_10_1093_ecco_jcc_jjab232_626 |
PublicationCentury | 2000 |
PublicationDate | 2022-01-21 |
PublicationDateYYYYMMDD | 2022-01-21 |
PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-21 day: 21 |
PublicationDecade | 2020 |
PublicationTitle | Journal of Crohn's and colitis |
PublicationYear | 2022 |
SSID | ssj0059578 |
Score | 2.3197749 |
Snippet | Abstract
Background
Higher infliximab trough levels (ITL) have been shown to be associated with better rates of clinical remission and mucosal healing.... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | i462 |
Title | P499 Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels? |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLa2TkLcIH618SdfcFdlS-L8mRvUFsqEVIRQJ-0usp1EzdSmqGkZcMVr8Bi8Ek_CObaTZmVCjJuotWzLyfkSH9vfdw4hLyLuZcorlJMzETlBIqU-33Vg9omzJMp4UqBQePI-Oj0L3p2H53v7hx3W0mYtj9W3a3Ul_2NVKAO7okr2BpZtO4UC-A32hStYGK7_ZOMPsJDAfA9IZYUV_2a-Xgnwn00U6lJh_oeqXujAGugQWvmKDaVqdW2j1XJWNZQHXjcnNjZ5OKzYTXjZvhFqfTWNStSSfCkXQuKOQj3DPNn9S2hULjRvcWbYI9tqMBSdDmiOHKV6h03YcYrNaPAMwejtkJzXev2TpTnXZ3p7tz0rGsOTrvtvl1Za0W77foTHqWkA9ZXjrxEWDgf4YkCjSleJxfyzaT3tboP4yCdxjLbafrmTmDmc2_3MvCkD_AUmW037uY86sNapU_U-bOp1PuNlYKeI_MrfP6YbE4oL3oKlc6EUzjwXQoKPehz518T33pl3Wzak4QGwFPtJoZ_U9pJCL_vkwI95GPfIwWD4ejhuvIwQyrTMs7ntRhbK2UkznpPOaDpuV8d_mt4ld6yN6cCg-B7Zy6v75NbEUjsekJ8IZtqCme6CmW7BTC2YaVnRBswUcUk1fH59_1FTC2OqYUxbGFMLY1N9i8-X1ICYXkKTckEBxNSAuFOJGhBTA-JXD8nZ-M10dOrYfCKO8sARdWQhhF_wgjFXMTfnYcZyF_xvKbwgTzLFhOcGWeTxIsEQSUzBUsH3ZJG4oohQgP6I9KpllR8SKn1fRNItVChlEOdccp6FifSTsAjRZz8iTvO4008mbEz6NzM_vmH9J-T29iV4Snrr1SZ_Bt7xWj63QPkNXNLCkw |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=P499+Accessing+ultrasonographic+transmural+healing+in+patients+with+Crohn%E2%80%99s+disease+after+induction+therapy+with+infliximab%3A+should+we+aim+for+higher+infliximab+trough+levels%3F&rft.jtitle=Journal+of+Crohn%27s+and+colitis&rft.au=Mor%C3%A3o%2C+B&rft.au=Frias+Gomes%2C+C&rft.au=Rev%C3%A9s%2C+J&rft.au=C%C3%BArdia+Gon%C3%A7alves%2C+T&rft.date=2022-01-21&rft.issn=1873-9946&rft.eissn=1876-4479&rft.volume=16&rft.issue=Supplement_1&rft.spage=i462&rft.epage=i462&rft_id=info:doi/10.1093%2Fecco-jcc%2Fjjab232.626&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ecco_jcc_jjab232_626 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-9946&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-9946&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-9946&client=summon |